Fate Therapeutics Inc (FATE) company profile

The company is a clinical-stage biopharmaceutical firm that develops off-the-shelf cellular immunotherapies using human induced pluripotent stem cells. Through cellular programming and multiplex engineering, it generates master cell lines to mass-produce uniform chimeric antigen receptor T-cell and natural killer cell therapies. Its principal product candidates include FT819, FT522, FT825, FT836, and FT839, which are designed to treat autoimmune disorders such as systemic lupus erythematosus, systemic sclerosis, vasculitis, and myositis, alongside advanced solid tumors. Its end users are patients with severe cancers and autoimmune conditions.

The company operates a good manufacturing practice facility exceeding 40,000 square feet to supply product candidates for clinical testing and commercial scale. Its clinical trials take place across the United States, the United Kingdom, and the European Union, including fourteen activated study sites located in the United States and the United Kingdom. Its proprietary platform is supported by over 600 issued patents and 550 pending patent applications. The provided document does not state where the company is headquartered.

Summary of the business section of Fate Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“Our common stock has been approved for listing on The NASDAQ Global Market under the symbol “FATE.” The initial public offering price of our common stock is $6.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we employed 161 employees, all of whom are full-time employees, including 27 in research and development, 103 in clinical development, manufacturing and regulatory affairs and 31 in general and administrative.”